Growth Metrics

Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2024 - 2026)

Prelude Therapeutics' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $8.5 million for Q1 2026.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 88.15% to $8.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $91.2 million, a 48.87% decrease, with the full-year FY2025 number at $154.4 million, up 7.48% from a year prior.
  • Change in Acquisitions & Divestments hit $8.5 million in Q1 2026 for Prelude Therapeutics, up from $6.4 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for PRLD hit a ceiling of $71.7 million in Q1 2025 and a floor of $6.4 million in Q4 2025.
  • Historically, Change in Acquisitions & Divestments has averaged $34.1 million across 3 years, with a median of $36.2 million in 2025.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 93.77% in 2025 and later tumbled 88.15% in 2026.
  • Tracing PRLD's Change in Acquisitions & Divestments over 3 years: stood at $29.5 million in 2024, then plummeted by 78.3% to $6.4 million in 2025, then surged by 32.8% to $8.5 million in 2026.
  • Business Quant data shows Change in Acquisitions & Divestments for PRLD at $8.5 million in Q1 2026, $6.4 million in Q4 2025, and $40.1 million in Q3 2025.